Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month ...

Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of personalized treatment decisions.

Furthermore, the addition of other targeted therapies that improve mTNBC survival rates like the PD-1 inhibitor (KEYTRUDA) may continue to raise awareness and implementation rates of alternative ...

However, at present, it is not quite clear whether Merck’s new products and pipeline candidates can help the company successfully navigate the Keytruda LOE period and potential competition for ...

Keytruda, the world's top-selling drug with nearly $30 billion in revenue last year, is nearing key patent expirations from 2028, and Merck has doubled down on efforts to reshape its portfolio.